Elanco Animal Health Incorporated Income Tax Examination, Penalties and Interest Expense
Elanco Animal Health Incorporated (ELAN) reported Income Tax Examination, Penalties and Interest Expense of -$1.00 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-28.
Discontinued › Expense Statement
us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense · last filed 2022-02-28
- Elanco Animal Health Incorporated income tax examination, penalties and interest expense for fiscal 2021 was -$1.00M.
- Elanco Animal Health Incorporated income tax examination, penalties and interest expense for fiscal 2020 was -$2.00M.
- Elanco Animal Health Incorporated income tax examination, penalties and interest expense for fiscal 2019 was -$11.00M.
- Elanco Animal Health Incorporated income tax examination, penalties and interest expense for fiscal 2018 was -$2.50M, a 200.00% decline from fiscal 2017.
| Period end | Income Tax Examination, Penalties and Interest Expense 12 month | Income Tax Examination, Penalties and Interest Expense 12 month as first filed |
|---|---|---|
| 2021-12-31 | -$1.00M 10-K · filed 2022-02-28 | |
| 2020-12-31 | -$2.00M 10-K · filed 2022-02-28 | -$1.70M 10-K · filed 2021-03-01 |
| 2019-12-31 | -$11.00M 10-K · filed 2022-02-28 | -$10.60M 10-K · filed 2020-02-28 |
| 2018-12-31 | -$2.50M 10-K · filed 2021-03-01 | |
| 2017-12-31 | $2.50M 10-K · filed 2020-02-28 | |
| 2016-12-31 | $5.50M 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |